52 related articles for article (PubMed ID: 21140395)
21. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
[TBL] [Abstract][Full Text] [Related]
22. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
23. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
24. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
25. Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays.
Pötz O; Schneiderhan-Marra N; Henzler T; Herget T; Joos TO
Methods Mol Biol; 2012; 795():191-202. PubMed ID: 21960224
[TBL] [Abstract][Full Text] [Related]
26. Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
Iwata H; Imamura S; Hori A; Hixon MS; Kimura H; Miki H
Bioorg Med Chem; 2011 Sep; 19(18):5342-51. PubMed ID: 21885287
[TBL] [Abstract][Full Text] [Related]
27. Universal and Quantitative Method To Evaluate Inhibitor Potency for Cysteinome Proteins Using a Nonspecific Activity-Based Protein Profiling Probe.
Sameshima T; Tanaka Y; Miyahisa I
Biochemistry; 2017 Jun; 56(23):2921-2927. PubMed ID: 28520393
[TBL] [Abstract][Full Text] [Related]
28. Recent developments in receptor tyrosine kinases targeted anticancer therapy.
Raval SH; Singh RD; Joshi DV; Patel HB; Mody SK
Vet World; 2016 Jan; 9(1):80-90. PubMed ID: 27051190
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase.
Mologni L; Tardy S; Zambon A; Orsato A; Bisson WH; Ceccon M; Viltadi M; D'Attoma J; Pannilunghi S; Vece V; Bertho J; Goekjian P; Scapozza L; Gambacorti-Passerini C
ACS Omega; 2022 May; 7(20):17083-17097. PubMed ID: 35647450
[TBL] [Abstract][Full Text] [Related]
30. Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.
Dao VH; Ourliac-Garnier I; Logé C; McCarthy FO; Bach S; da Silva TG; Denevault-Sabourin C; Thiéfaine J; Baratte B; Robert T; Gouilleux F; Brachet-Botineau M; Bazin MA; Marchand P
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770981
[TBL] [Abstract][Full Text] [Related]
31. An intramolecular inverse electron demand Diels-Alder approach to annulated α-carbolines.
Ma Z; Ni F; Woo GH; Lo SM; Roveto PM; Schaus SE; Snyder JK
Beilstein J Org Chem; 2012; 8():829-40. PubMed ID: 23015831
[TBL] [Abstract][Full Text] [Related]
32. Identification of potent EGFR inhibitors from TCM Database@Taiwan.
Yang SC; Chang SS; Chen HY; Chen CY
PLoS Comput Biol; 2011 Oct; 7(10):e1002189. PubMed ID: 22022246
[TBL] [Abstract][Full Text] [Related]
33. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
34. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
35. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
36. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
37. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
Toschi L; Cappuzzo F
Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitors.
Krug M; Wichapong K; Erlenkamp G; Sippl W; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2011 Jan; 6(1):63-72. PubMed ID: 21140395
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
